TNF Inhibitor denied as not FDA-approved for this use by Florida Blue?

Florida Blue uses Prime Therapeutics or CVS Caremark depending on plan line. Step therapy through preferred biosimilar.

FL Statute 627.42393 limits step therapy when prior failure documented. Demand peer-to-peer review. Cite continuity-of-care for stable patients.

## Why Florida Blue May Deny a TNF Inhibitor as "Not FDA-Approved"

TNF (tumor necrosis factor) inhibitors are a class of biologic medications used to treat several serious immune-mediated conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. A denial stating the drug is "not FDA-approved" for your specific indication typically means Florida Blue believes your diagnosis falls outside the labeled indications for the particular TNF inhibitor prescribed, or that the specific formulation or route of administration is not covered.

## Why This Denial Is Often Appealable

These denials frequently succeed on appeal when the prescriber can document that the prescribed TNF inhibitor carries an FDA-approved indication that precisely matches the patient's confirmed diagnosis. FDA approval status is objective and publicly verifiable. If the insurer has misclassified the indication or applied the wrong drug-indication pairing, that factual error alone can overturn the denial. Even where a use is technically "off-label," many state insurance laws and plan documents require coverage when there is adequate clinical support.

## Your Federal Appeal Rights

• Internal appeal: Submit a written internal appeal within the timeframe specified in your Explanation of Benefits (typically 180 days). Florida Blue must respond within 30 days for non-urgent pre-service requests and 60 days for post-service claims.
• External review (ACA §2719): After exhausting internal appeals — or if Florida Blue waives that requirement — you may request independent external review. An accredited Independent Review Organization (IRO) then issues a binding decision. The standard window to request external review is generally within four months of the final internal denial.
• Expedited review: If the standard timeline would seriously jeopardize your health, request expedited internal and external review simultaneously. Turnaround is typically 72 hours or less.
• ERISA §503: If your coverage is employer-sponsored, ERISA requires a full-and-fair review of every denied claim, with the right to examine all documents used in the decision.

## Documentation to Gather

1. Confirmed diagnosis — chart notes, lab results, imaging, or pathology that establish the precise ICD-coded condition matching an FDA-approved indication for the prescribed TNF inhibitor. 2. FDA-approved labeling — print the current Prescribing Information (available at DailyMed, fda.gov) and highlight the approved indications. This is your primary rebuttal to any "not approved" claim. 3. Prescriber medical-necessity letter — a detailed letter from your specialist explaining the diagnosis, why this specific TNF inhibitor was chosen, and how the indication aligns with FDA approval. 4. Relevant specialty-society guidelines — a reference to guidance from the applicable professional organization (e.g., ACR, AGA, AAD) supporting use of this drug class for your condition, without citing specific numeric thresholds.

## Criteria-Mapping Strategy

Structure your appeal as a point-by-point response: copy each requirement from Florida Blue's published medical policy for this drug, then supply the specific chart fact that satisfies it. For the FDA-approval question specifically, quote the exact indication language from the prescribing label and match it word-for-word to the diagnosis documented in the clinical record. This format forces the reviewer to engage with each element individually rather than issuing a blanket denial.